Glytec offers a clinician-directed algorithm for effective, standardized glycemic management throughout the hospital. Its software Glucommander provides a point-of-care technology solution for managing all insulin-requiring patients. Glucommander is an insulin dosing decision support algorithm that helps clinicians provide their patients with the personalized care. The company was founded in 2006 and is based in Waltham, Massachusetts.
Research containing Glytec
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Glytec in 3 CB Insights research briefs, most recently on Dec 7, 2022.
Expert Collections containing Glytec
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Glytec is included in 3 Expert Collections, including Value-Based Care & Population Health.
Value-Based Care & Population Health
The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Latest Glytec News
Aug 2, 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Glytec announced the latest version of its Glucommander insulin dosing software that makes it easier to offer best practice, personalized care.
Glytec Frequently Asked Questions (FAQ)
When was Glytec founded?
Glytec was founded in 2006.
Where is Glytec's headquarters?
Glytec's headquarters is located at 610 Lincoln Street, Waltham.
What is Glytec's latest funding round?
Glytec's latest funding round is Convertible Note - II.
How much did Glytec raise?
Glytec raised a total of $96.82M.
Who are the investors of Glytec?
Investors of Glytec include Savitr Capital, Silicon Valley Bank, Equity Resource Investments, Sea Dragon Healthcare Partners and Standard Pacific Capital.
Who are Glytec's competitors?
Competitors of Glytec include TransformativeMed.
Compare Glytec to Competitors
WellSheet is a company focused on improving the Electronic Health Record (EHR) experience in the healthcare industry. The company offers a predictive clinical workflow platform that integrates with existing EHR systems to provide clinicians with relevant and prioritized content, thereby reducing time spent in the EHR and improving patient care. The platform primarily serves the healthcare industry. It was founded in 2015 and is based in Newark, New Jersey.
Monarch Medical Technologies is a medical technology company that offers software-as-a-service solutions and services for glycemic control. It offers a product, named EndoTool Glucose Monitoring System that enhances hospital-based glucose management and is designed specifically to displace traditional manual methods of insulin dosing with a software application that integrates with all major EMR systems. The company was founded in 2003 and is based in Charlotte, North Carolina.
TransformativeMed is a company that focuses on healthcare technology. The company offers an intelligent care platform designed by clinicians for clinicians, providing specialty-specific content and workflows, enhanced care team collaboration, real-time data insights and notifications, and sophisticated glycemic management. The company primarily serves the healthcare industry. It was founded in 2011 and is based in Seattle, Washington.